Latrophilin-1 inhibitors are a class of chemical compounds that specifically target and inhibit the activity of Latrophilin-1, a member of the adhesion G-protein-coupled receptor (GPCR) family. Latrophilin-1 is involved in a variety of cellular processes, including cell adhesion, signaling, and synaptic organization. It is a receptor known for its interactions with extracellular ligands, such as toxins from the black widow spider, which originally led to its discovery. As a GPCR, Latrophilin-1 plays a role in mediating communication between cells and their external environment by activating intracellular signaling pathways upon ligand binding. By inhibiting Latrophilin-1, these compounds interfere with its signaling capabilities, potentially affecting processes like cell adhesion, communication, and organization.
The mechanism by which Latrophilin-1 inhibitors function typically involves blocking the receptor's ligand-binding site or interfering with its interaction with other cellular components, such as cytoskeletal proteins or signaling molecules. This disruption of Latrophilin-1 activity can alter the signaling cascades it controls, particularly those related to cell-cell interactions and the organization of synaptic structures. Researchers use Latrophilin-1 inhibitors to explore the role of this receptor in neuronal communication, cell adhesion, and the organization of tissues, as it is known to participate in key signaling networks that regulate these processes. The inhibition of Latrophilin-1 provides a valuable tool for studying the molecular mechanisms by which GPCRs like Latrophilin-1 influence cellular dynamics and how their modulation impacts broader biological functions such as synapse formation, cellular migration, and tissue architecture.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Clozapine | 5786-21-0 | sc-200402 sc-200402A sc-200402B sc-200402C | 50 mg 500 mg 5 g 10 g | $69.00 $364.00 $2500.00 $4100.00 | 11 | |
Clozapine may inhibit LPHN1 expression by modulating various neurotransmitter receptors and influencing synaptic activities. | ||||||
Haloperidol | 52-86-8 | sc-507512 | 5 g | $190.00 | ||
Haloperidol could affect LPHN1 expression by antagonizing dopamine receptors, impacting neural connectivity and signaling. | ||||||
Olanzapine | 132539-06-1 | sc-212469 | 100 mg | $133.00 | 6 | |
Olanzapine might influence LPHN1 expression by interacting with various neurotransmitter receptors, affecting neural communication. | ||||||
Risperidone | 106266-06-2 | sc-204881 sc-204881A sc-204881B sc-204881C | 10 mg 50 mg 1 g 5 g | $174.00 $719.00 $1020.00 $2040.00 | 1 | |
Risperidone may affect LPHN1 expression by modulating serotonin and dopamine receptors, influencing neural signaling pathways. | ||||||
(+)-Bicuculline | 485-49-4 | sc-202498 sc-202498A | 50 mg 250 mg | $82.00 $281.00 | ||
Bicuculline might influence LPHN1 expression by antagonizing GABA receptors, impacting inhibitory neurotransmission. | ||||||
6-Cyano-7-nitroquinoxaline-2,3-dione | 115066-14-3 | sc-505104 | 10 mg | $208.00 | 2 | |
CNQX could affect LPHN1 expression by blocking AMPA receptors, influencing excitatory neurotransmission. | ||||||
D(−)-2-Amino-5-phosphonovaleric acid (D-AP5) | 79055-68-8 | sc-200434 | 5 mg | $97.00 | 2 | |
D-AP5 may inhibit LPHN1 expression by blocking NMDA receptors, affecting glutamatergic signaling. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 could inhibit LPHN1 expression by targeting PI3K, affecting intracellular signaling pathways. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 may affect LPHN1 expression by inhibiting MEK, impacting ERK signaling pathways in neurons. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB431542 might inhibit LPHN1 expression by targeting TGF-beta receptors, influencing cellular differentiation and growth. | ||||||